DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Nalmefene Smoking Cessation Study

Information source: Somaxon Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Smoking Cessation

Intervention: nalmefene (Drug); Placebo (Other)

Phase: Phase 2

Status: Completed

Sponsored by: Somaxon Pharmaceuticals

Official(s) and/or principal investigator(s):
Philip Jochelson, MD, Study Director, Affiliation: Somaxon Pharmaceuticals CMO

Summary

To determine if nalmefene is safe and effective in smoking cessation.

Clinical Details

Official title: A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Assess the efficacy of 2 doses of nalmefene relative to placebo

Secondary outcome: Evaluate the safety and tolerability of 2 doses of nalmefene

Detailed description: Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.

Eligibility

Minimum age: 25 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Smokers in good general health self reporting more than 15 cigarettes per day

Exclusion Criteria:

-

Locations and Contacts

Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information

Starting date: September 2005
Last updated: May 15, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017